
Affimed (AFMD) Stock Forecast & Price Target
Affimed (AFMD) Analyst Ratings
Bulls say
Affimed NV's positive outlook is supported by a decrease in operating expenses, leading to increased earnings per share (EPS) estimates for 2025, and an improved probability of success (PoS) for the AFM13 combination therapy in Hodgkin lymphoma, which was raised from 70% to 80%. The company is generating promising results with its AFM24 and AFM28 therapies, where AFM28 has exhibited the highest complete response (CR) and complete response with incomplete recovery (CRi) rates among anti-CD123 therapies, indicating its potential for market leadership. Additionally, the favorable safety and tolerability profile of AFM28 positions it as a viable combination therapy in the refractory/relapsed setting, further enhancing its attractiveness to potential partners for commercialization.
Bears say
Affimed NV, a clinical-stage biopharmaceutical company specializing in cancer immunotherapies, reported total revenues of only €0.2 million for the third quarter of 2024, significantly lower than the consensus estimate of €1.5 million. Furthermore, the company faced a net loss of €0.94 per share, which is slightly higher than the consensus loss estimate of €0.92 per share, indicating ongoing financial challenges. Additionally, with only €48.5 million in cash as of March 31, 2024, and a guided cash runway into the second half of 2025, the company is at risk of potential financing issues that could hinder its operational capabilities and development timeline.
This aggregate rating is based on analysts' research of Affimed and is not a guaranteed prediction by Public.com or investment advice.
Affimed (AFMD) Analyst Forecast & Price Prediction
Start investing in Affimed (AFMD)
Order type
Buy in
Order amount
Est. shares
0 shares